Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Sulfonylurea Glimepiride

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01794143Phase 3Completed

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Showing all 1 trials

Research Network

Common Treatments

  • Sulfonylurea Glimepiride1
  • Glp1 Receptor Agonist Liraglutide1
  • Dpp4 Inhibitor Sitagliptin1
  • Insulin Glargine1

Active Sponsors

  • National Heart, Lung, and Blood Institute (NHLBI)1
  • GRADE Study Group1
  • Centers for Disease Control and Prevention1
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1

Top Investigators

Related Conditions

  • Type 2 Diabetes1

Activity Timeline